Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes
- PMID: 20217528
- DOI: 10.1007/978-3-642-00477-3_4
Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes
Abstract
The main aim of pharmaceutical technology research is the design of successful formulations for effective therapy, taking into account several issues including therapeutic requirements and patient compliance. In this regard, several achievements have been reported with colloidal carriers, in particular with lipid nanoparticles, due to their unique physicochemical properties. For several years these carriers have been showing potential success for several administration routes, namely oral, dermal, parenteral, and, more recently, for pulmonary and brain targeting. The present chapter provides a review of the use of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) to modify the release profile and the pharmacokinetic parameters of active pharmaceutical ingredients (APIs) incorporated in these lipid matrices, aiming to modify the API bioavailability, either upwards or downwards depending on the therapeutic requirement. Definitions of the morphological characteristics, surface properties, and polymorphic structures will also be given, emphasizing their influence on the incorporation parameters of the API, such as yield of production, loading capacity, and encapsulation efficiency.
Similar articles
-
Solid lipid nanoparticles for parenteral drug delivery.Adv Drug Deliv Rev. 2004 May 7;56(9):1257-72. doi: 10.1016/j.addr.2003.12.002. Adv Drug Deliv Rev. 2004. PMID: 15109768 Review.
-
Lipid nanoparticles for parenteral delivery of actives.Eur J Pharm Biopharm. 2009 Feb;71(2):161-72. doi: 10.1016/j.ejpb.2008.09.003. Epub 2008 Sep 13. Eur J Pharm Biopharm. 2009. PMID: 18824097 Review.
-
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products.Int J Pharm. 2009 Jan 21;366(1-2):170-84. doi: 10.1016/j.ijpharm.2008.10.003. Epub 2008 Oct 17. Int J Pharm. 2009. PMID: 18992314 Review.
-
Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery.Methods Enzymol. 2009;464:105-29. doi: 10.1016/S0076-6879(09)64006-4. Methods Enzymol. 2009. PMID: 19903552
-
Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.Acta Pharmacol Sin. 2008 Sep;29(9):1094-102. doi: 10.1111/j.1745-7254.2008.00829.x. Acta Pharmacol Sin. 2008. PMID: 18718178
Cited by
-
Evaluation of the Influence of Process Parameters on the Properties of Resveratrol-Loaded NLC Using 22 Full Factorial Design.Antioxidants (Basel). 2019 Aug 3;8(8):272. doi: 10.3390/antiox8080272. Antioxidants (Basel). 2019. PMID: 31382599 Free PMC article.
-
Investigating Antiarthritic Potential of Nanostructured Clove Oil (Syzygium aromaticum) in FCA-Induced Arthritic Rats: Pharmaceutical Action and Delivery Strategies.Molecules. 2021 Dec 2;26(23):7327. doi: 10.3390/molecules26237327. Molecules. 2021. PMID: 34885909 Free PMC article.
-
(+)-Limonene 1,2-Epoxide-Loaded SLNs: Evaluation of Drug Release, Antioxidant Activity, and Cytotoxicity in an HaCaT Cell Line.Int J Mol Sci. 2020 Feb 20;21(4):1449. doi: 10.3390/ijms21041449. Int J Mol Sci. 2020. PMID: 32093358 Free PMC article.
-
Preparation, Characterization, and Antiangiogenic Evaluation of a Novel 5-Fluorouracil Derivative Solid Lipid Nanoparticle with a Hen's Egg Chorioallantoic Membrane Assay and Wound Healing Response in HaCaT Keratinocytes.ACS Omega. 2024 Mar 25;9(14):16640-16647. doi: 10.1021/acsomega.4c00635. eCollection 2024 Apr 9. ACS Omega. 2024. PMID: 38617689 Free PMC article.
-
Core-based lipid nanoparticles as a nanoplatform for delivery of near-infrared fluorescent imaging agents.Am J Nucl Med Mol Imaging. 2014 Sep 6;4(6):507-24. eCollection 2014. Am J Nucl Med Mol Imaging. 2014. PMID: 25250201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources